FibroGen, Inc. — Form 10-Q Summary
Filing identity: The request metadata names Kyntra Bio, Inc., but the supplied filing identifies FibroGen, Inc. (Nasdaq: FGEN) as the registrant. Verify that this is the intended filing. Reporting period: quarter ended March 31, 2021; filed May 10, 2021. Financial statements are unaudited.
Business context
FibroGen is a biopharmaceutical company developing and commercializing therapies for anemia, fibrotic disease and cancer. Roxadustat was being commercialized for CKD-related anemia in China and Japan and was approved in Chile; U.S. and European regulatory reviews remained pending. Pamrevlumab was in Phase 3 development for idiopathic pulmonary fibrosis (IPF), pancreatic cancer and Duchenne muscular dystrophy (DMD).
Financial performance and position
| Metric | Q1 2021 | Q1 2020 / prior date |
|---|---|---|
| Total revenue | $38.4 million | $24.4 million; up 57% |
| Operating costs and expenses | $108.9 million | $105.5 million; up 3% |
| Operating loss | $70.4 million | $81.1 million |
| Net loss | $71.8 million | $78.3 million |
| Net loss per share, diluted | $0.78 | $0.89 |
| Operating cash flow | $(45.0) million | $(59.5) million |
| Cash and cash equivalents | $433.5 million | $678.4 million at Dec. 31, 2020 |
| Short- and long-term investments | $204.4 million | $8.4 million at Dec. 31, 2020 |
| Accounts receivable | $40.5 million | $41.9 million at Dec. 31, 2020 |
| Total assets / total liabilities | $787.3 million / $397.0 million | $826.8 million / $385.4 million at Dec. 31, 2020 |
Revenue comprised $14.6 million of development and other revenue, $15.4 million of net roxadustat product revenue in China and $8.5 million of drug-product revenue. Gross profit was approximately $35.0 million, or 91% of revenue, based on reported revenue less cost of goods sold of $3.4 million; this is not a measure of overall profitability. R&D expense was $74.7 million, versus $54.9 million; SG&A was $30.8 million, versus $49.6 million.
Cash, cash equivalents and investments totaled $637.9 million at quarter-end; adding accounts receivable gives $678.5 million, as reported by management. The $244.9 million quarterly decline in cash and cash equivalents primarily reflected $196.2 million of purchases of available-for-sale securities, not solely operating burn. FibroGen reported $34.7 million in finance lease liabilities, $5.1 million in operating lease liabilities and $18.0 million in product development obligations. The filing reports no conventional borrowing balance.
Material changes versus prior comparable period
- Revenue rose $14.0 million, led by the start of sales to China distribution venture Falikang and $8.5 million in drug-product revenue; development revenue fell 25% to $14.6 million.
- Net loss narrowed by $6.6 million, although total operating expenses increased $3.4 million. Higher clinical-trial, employee and stock-compensation expenses were partly offset by lower SG&A, mainly reflecting changed China co-promotion expense arrangements.
- R&D expense increased 36%, including higher spending on pamrevlumab Phase 3 trials and roxadustat post-approval safety studies. SG&A decreased 38%.
- Cash and cash equivalents fell $244.9 million, while the company shifted substantially more funds into investments. Cash flow used in operations improved by $14.5 million year over year.
Outlook, commentary and risks
- Management said existing cash, investments and receivables were expected to fund anticipated cash requirements for at least 12 months from the filing date, while also anticipating continuing losses and substantial funding needs. This is a forward-looking estimate, not a guarantee.
- The FDA had tentatively scheduled an advisory committee meeting on roxadustat for July 15, 2021. The company said the committee’s views could affect approval prospects and labeling. Astellas expected an EMA decision around mid-2021.
- Management expected MATTERHORN roxadustat MDS topline data in the first half of 2022, WHITNEY chemotherapy-induced anemia data in the second half of 2021, and LAPIS pancreatic-cancer resection data and LELANTOS-1 DMD data in the second half of 2022. No revenue or earnings guidance was provided.
- COVID-19 had slowed clinical-trial enrollment, particularly in the IPF program; management said Q1 financial results were not significantly affected relative to prior quarters, but future effects were uncertain.
- Revenue recognition for China sales and drug-product shipments depends on estimates of variable consideration. The company deferred $3.9 million related to Falikang sales and $11.8 million for Astellas pre-commercial supply pending resolution of uncertainty.
- Disclosure controls were deemed ineffective due to material weaknesses in risk assessment and controls over identifying drug-product shipments and changes in estimated variable consideration. Remediation was in progress and not yet complete.
- Five putative securities class actions were reported as filed in April and May 2021, after quarter-end, alleging misleading statements about Phase 3 data and FDA prospects. The company disputed the claims; potential exposure was not estimable.
- Other notable exposures include $93.9 million of non-cancelable purchase obligations, reliance on collaboration partners and single-source supply arrangements, regulatory and clinical-trial uncertainty, competition, China operating and cash-transfer restrictions, and pricing/reimbursement risk.
Important facts for investors to verify
- Confirm the intended registrant: the supplied filing is FibroGen, not Kyntra Bio.
- Check subsequent FDA and EMA actions on roxadustat, including advisory committee conclusions, approval timing and any label or safety requirements.
- Review later filings for progress in remediating the material weaknesses and whether controls were independently tested and deemed effective.
- Track China roxadustat sales, Falikang economics, deferred-revenue estimates and collection of related-party receivables.
- Assess cash burn and liquidity against trial spending, purchase commitments, lease obligations and management’s 12-month funding estimate.
- Monitor the securities litigation and any change in the company’s assessment of potential loss or disclosure.